Investors & Media - BrainStorm Cell Therapeutics

News

Press Releases

Month Year

Investor Alerts

Oct 3, 2018

BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS

NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences

NEW YORK and PETACH TIKVAH, Israel, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for...
- Photos 1
Sep 13, 2018

BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®

NEW YORK and PETACH TIKVAH, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
- Photos 1
Sep 12, 2018

BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform

NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating...
- Photos 1
Sep 5, 2018

BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference

Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET

NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Photos 1
Sep 4, 2018

BrainStorm Appoints Arturo Araya as Chief Commercial Officer

BrainStorm Appoints Arturo Araya as Chief Commercial Officer

NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
- Photos 1
Aug 29, 2018

BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference

NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Photos 1
Aug 23, 2018

BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS

NEW YORK, and PETACH TIKVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative...
- Photos 1
Jul 25, 2018

BrainStorm Announces Grant of a New European Patent for NurOwn®

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has...
- Photos 1
Jul 23, 2018

BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update

Conference Call and Webcast at 8.30am ET Today

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second quarter and...
- Photos 1
Jul 17, 2018

BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23

Conference Call and Live Webcast at 8.30am ET

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended...